A low-cost, self-powered pen with magnetic ink may help detect early signs of Parkinson’s disease by analyzing handwriting. When the pen was tested, it was able to distinguish Parkinson’s patients from healthy people with an average accuracy of 96%, a study reports. “Detection of subtle motor symptoms unnoticeable to…
The U.S. Food and Drug Administration has approved Exablate Neuro, Insightec’s platform for noninvasive, MRI-guided focused ultrasound therapy, for the bilateral treatment of motor symptoms in patients with advanced Parkinson’s disease who no longer respond to medication. The therapy targets regions within the pallidothalamic tract, a brain pathway…
Ambroxol, a common cough medicine, may help stabilize neuropsychiatric symptoms in Parkinson’s disease dementia (PDD) and shows cognitive promise for patients with mutations in the GBA1 gene, according to results from a Phase 2 clinical trial. While ambroxol is widely used in Europe to treat respiratory conditions, it’s not approved…
Genetic analysis of saliva may offer a noninvasive way to assess the risk of developing Parkinson’s disease, according to a saliva-based DNA study led by researchers at the University of the Basque Country (EHU) in Spain. The scientists found that molecular markers in saliva can reflect whole-body disease processes,…
Pharmather is advancing its ketamine-based treatment for Parkinson’s disease as the approval decision date of Aug. 9, 2025, set by the U.S. Food and Drug Administration (FDA) draws closer. If approved, the company plans to market the product under the brand name Ketarx and expand its use in neurological conditions,…
Target enrollment for a Phase 1b clinical study assessing the safety and tolerability of GT-02287 in people with Parkinson’s disease is complete, three months ahead of the original goal, the therapy’s developer said. After enrolling the first 16 participants, the Phase 1b clinical trial (NCT06732180) is recruiting up…
People in the prodromal, or presymptomatic, stage of Parkinson’s disease show increased immune activity, with T cells targeting the proteins PINK1 and alpha-synuclein at levels similar to those seen in patients already diagnosed with the neurodegenerative condition, a new study reports. These two proteins — PINK1 and alpha-synuclein —…
BioVie’s ongoing SUNRISE-PD clinical trial of bezisterim in early Parkinson’s disease uses a hybrid, decentralized approach to center patient experience and promote accessibility, according to the company. Parkinson’s disease patients often face barriers to accessing specialized care and participating in clinical trials due to delayed diagnosis, limited mobility, and…
A trio of prominent Parkinson’s disease advocacy groups are calling on the U.S. federal government to provide strong funding and support for the National Institutes of Health (NIH) — a federal agency that is a major driver of biomedical research around the world. The American Parkinson Disease Association,…
Copper supplementation that reaches the brain reduces the signs and symptoms of Parkinson’s disease in a mouse model, a study found. Researchers found that copper restored the function of SOD1, an antioxidant enzyme that’s prone to misfolding and forming toxic clumps, impairing the function of dopamine-producing nerve cells that…
Get regular updates to your inbox.
